Strides Arcolab has slipped by 4% at Rs 865 in an otherwise firm market after the pharmaceutical company said has received a warning letter from the United States Food and Drug Administration (US FDA) for its sterile manufacturing facility at Bangalore.
The sterile manufacturing facility 2 at Bangalore of Agila Specialties Private Limited, a wholly owned subsidiary of the company, has received a warning letter from the USFDA, Strides Arcolab said in a regulatory filing.
The company is committed to work collaboratively and expeditiously with the USFDA to resolve concerns cited in the warning letter in the shortest possible time, it added.
Meanwhile, the company said its oncology facility at Bangalore of Agila Specialties Private Limited was also inspected recently by the USFDA and this facility has cleared the inspection with "Zero 483 status".
The company has 8 USFDA approved sterile manufacturing facilities.
The stock opened at Rs 902 and hit a low of Rs 840 on NSE. A combined 323,379 shares change hands on the counter so far on NSE and BSE.
The sterile manufacturing facility 2 at Bangalore of Agila Specialties Private Limited, a wholly owned subsidiary of the company, has received a warning letter from the USFDA, Strides Arcolab said in a regulatory filing.
The company is committed to work collaboratively and expeditiously with the USFDA to resolve concerns cited in the warning letter in the shortest possible time, it added.
Meanwhile, the company said its oncology facility at Bangalore of Agila Specialties Private Limited was also inspected recently by the USFDA and this facility has cleared the inspection with "Zero 483 status".
The company has 8 USFDA approved sterile manufacturing facilities.
The stock opened at Rs 902 and hit a low of Rs 840 on NSE. A combined 323,379 shares change hands on the counter so far on NSE and BSE.
